Advancements in Medical and Surgical Treatments of Takayasu Arteritis-Induced Renal Arteritis: A Systematic Review

0
0
0

Advancements in Medical and Surgical Treatments of Takayasu Arteritis-Induced Renal Arteritis: A Systematic Review

Takayasu arteritis (TA), a rare inflammatory disease that targets large blood vessels, affects mostly women under 40—and when it invades the renal arteries, it can lead to life-threatening complications like severe hypertension, kidney damage, or even stroke. This specific form, called Takayasu arteritis-induced renal arteritis (TARA), is now a top cause of poor outcomes for TA patients. If left untreated, TARA progresses to Takayasu arteritis-induced renal artery stenosis (TARAS), where the renal artery narrows or blocks, triggering a cascade of problems: high blood pressure (from overactive RAAS, the body’s blood pressure regulator), reduced kidney function, and strain on the heart and brain. Until recently, there were no clear guidelines for treating TARA—so researchers set out to review the latest evidence on how to help patients.

What the Study Found

A team from the Department of Rheumatology at Zhongshan Hospital, Fudan University (Shanghai, China) analyzed 82 studies (34 on medical treatments, 48 on surgery) from global databases like PubMed, EMBASE, and Chinese platforms (CNKI, Wanfang) covering data up to May 2018. The goal? To identify the most effective ways to manage TARA—from controlling inflammation to fixing damaged arteries.

Part 1: Medical Treatments—Stopping Inflammation First

The first line of defense against TARA is anti-inflammatory medication, which targets the immune system’s overactivity that drives artery damage. Here’s what works:

1. Glucocorticoids (GCs): The “Cornerstone”—But Not Enough Alone

GCs like prednisone are the standard starting point for reducing inflammation. They work for about 60% of patients, but only 20% achieve long-term remission with GCs alone. Most (80%) need combination therapy with other drugs to prevent flare-ups.

  • Dosage: 0.5–1 mg/kg daily for 4–8 weeks, then tapered to 5–10 mg daily for 1–2 years.
  • Catch: GCs don’t stop disease recurrence, and long-term use causes side effects (e.g., bone loss, diabetes).

2. Conventional DMARDs (cDMARDs): Boosting GC Effectiveness

cDMARDs (disease-modifying anti-rheumatic drugs) are added to GCs to slow disease progression. The best options depend on how severe the disease is:

  • Methotrexate (MTX): 75–81% remission rate, cuts GC doses, but 54% of patients relapse. Side effects: stomach issues, liver problems.
  • Leflunomide (LEF): 80% remission, fewer side effects, but 13% have artery damage progression.
  • Mycophenolate mofetil (MMF): 75–90% remission, lowers inflammation markers.
  • Cyclophosphamide (CTX): Best for severe cases (82–100% remission), improves blood pressure and kidney function. But high doses risk serious side effects (e.g., infections, bladder damage in Caucasians; stomach issues in Asians).

3. Biologic DMARDs (bDMARDs): For “Refractory” Cases

If GCs and cDMARDs fail (called refractory TARA), biologic drugs target specific immune proteins. Two main types:

  • Tocilizumab (TCZ): Blocks interleukin-6 (IL-6), a protein driving inflammation. 64–100% remission in small studies, with GC doses dropping from 12.5–40 mg to 4.5–5 mg daily. But a large Japanese trial found no difference in relapse rates vs. placebo.
  • TNF Inhibitors (e.g., infliximab): 74–93% remission, but 33–62% of patients relapse. Infliximab works best, but patients must be screened for latent tuberculosis or HBV before use.

Part 2: Surgical Treatments—Fixing Blocked Arteries

When inflammation is controlled but arteries are severely narrowed or blocked, surgery can rebuild blood flow to the kidneys. The key rule: never operate on active inflammation—it raises risk of complications or death.

1. Endovascular Interventions: Minimally Invasive First

  • Percutaneous Transluminal Angioplasty (PTA): The first choice for TARAS. A balloon is threaded through a blood vessel to widen the stenosis.

    • Success rate: 91.6%
    • Hypertension outcomes: 49% cured, 43% improved.
    • Long-term: 91% of arteries stay open after 5 years; only 17% restenose.
    • Drawbacks: Hard to use on severe abdominal aortic or proximal renal artery stenosis.

  • Stents: Used for ostial (opening) or long lesions, or aneurysms. But stents have a 48% restenosis rate (vs. 17% for PTA) and lower 5-year patency (35%). They’re a last resort for PTA failures.

2. Open Surgery: Better Long-Term, But Riskier

Open procedures (e.g., aortic-renal artery bypass) are more invasive but offer better long-term results:

  • Hypertension improvement: 57%
  • 1-year patency: 92.7%
  • 5-year patency: 81.5%
  • Risks: Early complications (infection, bleeding), late issues (restenosis, stroke).

The Big Takeaway: Combine Medical and Surgical Care

The study’s most important message? TARA can’t be treated with drugs or surgery alone—you need both, plus a multidisciplinary team (MDT). Rheumatologists manage inflammation; vascular surgeons fix arteries; nephrologists protect kidney function; and cardiologists monitor heart health.

  • Active TARA: Start with GC + cDMARDs. Use CTX for severe cases; bDMARDs if first-line fails.
  • Chronic TARAS: After inflammation is controlled, choose PTA (first) or open surgery (for complex cases).

Why This Matters for Patients

TARA is a silent threat—many patients don’t know they have it until kidney or heart damage occurs. This review gives doctors a clear framework: control inflammation first, then fix arteries. But there’s still work to do:

  • No standardized guidelines for TARA treatment.
  • Most studies are small or retrospective (not randomized trials).
  • More research is needed on biologic drugs and long-term outcomes.

For patients with TA, the message is hope: early, combined treatment can slow TARA progression and save lives. If you have TA, ask your doctor about renal artery screening—catching TARA early makes all the difference.

This study was published in the Chinese Medical Journal (2020;133(8)) by Xiao-Min Dai, Meng-Meng Yin, Yun Liu, Li-Li Ma, Jun Ying, and Lin-Di Jiang from Zhongshan Hospital, Fudan University, Shanghai, China.

doi.org/10.1097/CM9.0000000000000704

Was this helpful?

0 / 0